Which stock wins in a battle between these two liver-disease-focused biotechs?
News & Analysis: GENEFIT
A small company is working on new ways to tackle a life-threatening liver disease.
This upstart is developing a diagnostic test and treatment for nonalcoholic steatohepatitis, or NASH, an increasingly common liver disease.
A NASH dash is on -- and these drugmakers could come out on top.
Gilead Sciences might want to pay attention to Allergan's aggressive expansion of its NASH program.
Genfit and Intercept could be on track to beat bigger players Allergan and Gilead in the potentially lucrative NASH market.